Exploiting aneuploidy in NF1-mpnst: prognostication and understanding pathogenesis

This Project Grant award from the Department of the Army Medical Command totals $894,263 to The Washington University for the period of September 1, 2022 through August 31, 2025. The award supports research under the Military Medical Research and Development program (CFDA 12.420) to further understanding of the pathogenesis and prognostication of malignant peripheral nerve sheath tumors (MPNSTs) associated with Neurofibromatosis type 1 (NF1).

Under the award, The Washington University will generate patient-derived xenograft models of NF1-MPNST and conduct multi-omics analyses to correlate molecular profiles with drug response and clinical outcomes. Sage Bionetworks and the Pacific Northwest National Laboratory (PNNL) receive subawards totaling $894,263 to support data sharing and predictive modeling respectively. Specifically, Sage Bionetworks will ensure raw data from the project is findable, annotated and shared on appropriate repositories to maximize reuse. PNNL will evaluate patient tumor sequencing data, develop computational models to predict drug response from genomics, and measure protein expression in MPNST samples to identify biomarkers.